Survodutide heads to EASD 2026 with no US filing date disclosed
Survodutide's type 2 diabetes data arrive Oct. 1, but the experimental weight-loss drug still has no disclosed US filing date, so patients cannot count on it as a near-term option.
Boehringer Ingelheim has not disclosed a US filing date or an expected launch for survodutide, its experimental weekly weight-loss injection, as the drug heads to a major diabetes meeting with new data in people who have type 2 diabetes [1][2].
Survodutide is a glucagon/GLP-1 receptor dual agonist. It is investigational and has not been approved for use, and its efficacy and safety have not been established, the company said in its April 28 topline release [1].
The European Association for the Study of Diabetes (EASD) 2026 congress runs Sept. 28 to Oct. 2 in Milan. Primary results from SYNCHRONIZE-2, which tested survodutide in adults with obesity or overweight and type 2 diabetes, are scheduled for Oct. 1, according to a post by the account @JCanNuSH that lists the meeting's GLP-1 presentations [2]. Boehringer's April release confirmed that SYNCHRONIZE-2 enrolled a subpopulation of adults with type 2 diabetes but did not say when results would be available [1].
The SYNCHRONIZE-1 topline release, published April 28, 2026, covered 725 adults with obesity or overweight but without type 2 diabetes. Participants received weekly injections of survodutide at 3.6 mg or 6.0 mg, or placebo, for 76 weeks [1].
Treated participants lost up to an average of 16.6% of body weight, or about 39.2 lb (17.8 kg), compared with 3.2% in the placebo group (p<0.0001) using the efficacy estimand. Up to 85.1% of treated participants lost at least 5% of body weight, versus 38.8% on placebo (p<0.0001) [1].
The release gives those numbers as the top of a range across the two doses and does not break out weight loss by dose. The efficacy estimand assumes patients stayed on treatment for the full study, and the company notes those p-values are nominal [1]. The trial also met a key secondary endpoint on waist circumference, and the company said initial analysis indicated the weight loss came mostly from fat tissue, with lean mass making up a small share of the total [1].
Gastrointestinal side effects occurred as expected with GLP-1-based therapies. They were mild to moderate and temporary, and discontinuations happened more often during the dose-escalation phase. The company reported no new safety concerns beyond what is expected for the drug class [1].
Regulators have not cleared survodutide for sale. The FDA granted it Fast Track designation in May 2021 and Breakthrough Therapy designation in September 2024 for adults with non-cirrhotic MASH and moderate or advanced fibrosis (stages 2 or 3). The European Medicines Agency accepted it into its PRIME scheme in November 2023 [1].
Two Phase 3 liver trials are under way. LIVERAGE is expected to enroll about 1,800 adults and LIVERAGE-Cirrhosis about 1,590, both testing weekly survodutide at a maximum dose of 6 mg against placebo. A cardiovascular outcomes trial, SYNCHRONIZE-CVOT, has also enrolled participants [1].
Why it matters for patients
The practical point is timing. Survodutide cannot be prescribed in the US, and the company has not said when it might file for approval or bring the drug to market, so there is no launch date to plan around [1].
The October data will speak to a group that SYNCHRONIZE-1 excluded. People with type 2 diabetes were not part of the earlier trial, so the EASD presentation is the first look at Phase 3 results in that population [1][2]. Boehringer has not released SYNCHRONIZE-2 numbers, so how survodutide performed in people with type 2 diabetes has not been reported.
Survodutide's liver program is a separate track. The company estimates that up to 1 in 3 people living with obesity develop MASH, a progressive liver disease, and says glucagon agonism is thought to act directly on the liver to reduce liver fat, regulate metabolic function, resolve inflammation and improve fibrosis [1]. Whether the drug improves liver outcomes is still being tested in the LIVERAGE trials [1].
No head-to-head trial of survodutide against an approved weight-loss medicine has been reported.
What happens next
- Sept. 28 to Oct. 2, 2026: EASD 2026 in Milan, with SYNCHRONIZE-2 primary data scheduled for Oct. 1 [2].
- November 2026: The American Heart Association Scientific Sessions and Obesity Week follow, according to the same conference preview [2].
- The company has said additional results from its SYNCHRONIZE obesity program are expected during 2026 [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.